Geraci Giulio, Sorce Alessandra, Zanoli Luca, Cuttone Giuseppe, Calabrese Vincenzo, Pallotti Francesco, Paternò Valentina, Ferrara Pietro, Dominguez Ligia J, Polosa Riccardo, George Jacob, Mulè Giuseppe, Carollo Caterina
Department of Medicine and Surgery, Kore University of Enna, 94100 Enna, Italy.
Unit of Nephrology and Dialysis, Hypertension Excellence Centre, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90133 Palermo, Italy.
Life (Basel). 2025 Mar 4;15(3):401. doi: 10.3390/life15030401.
8-iso-prostaglandin-F (8-iso-PGF) is a recognized marker of oxidative stress. Previous studies suggested that 8-iso-PGF plays an important role in the pathogenesis of hypertension and cardiovascular (CV) diseases. However, limited data exist on the prognostic role of 8-iso-PGF in hypertensive patients undergoing primary prevention. The aim of this study was to assess the relationship between 8-iso-PGF and 10-year CV risk, as predicted by validated equations in hypertension patients without CV diseases.
A total of 432 individuals aged 40-75 years were enrolled. Plasma 8-iso-PGF was assessed through the ELISA method. CV risk was calculated by using the Framingham Risk Score (Fr-S) and the Atherosclerosis Cardiovascular Disease Risk Score (ASCVD-S). Low, moderate, or high CV risks were defined according to validated cutoffs.
Individuals with higher CV risk had significantly greater 8-iso-PGF values compared to those with low or moderate CV risk ( < 0.001). 8-iso-PGF correlated strongly with Fr-S and ASCVD-S in the entire population and in patients with normal renal function (all < 0.001) but not in patients with eGFR < 60 mL/min/1.73 m. These associations remained significant after adjustment for traditional factors included in the CV risk equations in the overall population and in patients with normal renal function. The 8-iso-PGF cutoffs that best distinguished patients with high CV risk were 310 pg/mL for Fr-S and 264 pg/mL for ASCVD-S in the overall population, with significant differences between the groups divided by eGFR (all < 0.001).
These findings highlight the potential utility of 8-iso-PGF as a biomarker for refining cardiovascular risk stratification in hypertensive patients, particularly those with preserved renal function. Future studies should explore its prognostic value in longitudinal cohorts and assess its integration into clinical risk models to enhance early prevention strategies for cardiovascular disease.
8-异前列腺素F（8-iso-PGF）是一种公认的氧化应激标志物。先前的研究表明，8-iso-PGF在高血压和心血管疾病的发病机制中起重要作用。然而，关于8-iso-PGF在接受一级预防的高血压患者中的预后作用的数据有限。本研究的目的是评估8-iso-PGF与10年心血管风险之间的关系，该风险由经过验证的方程预测，针对无心血管疾病的高血压患者。
共纳入432名年龄在40-75岁之间的个体。通过酶联免疫吸附测定法评估血浆8-iso-PGF。使用弗明汉风险评分（Fr-S）和动脉粥样硬化性心血管疾病风险评分（ASCVD-S）计算心血管风险。根据经过验证的临界值定义低、中或高心血管风险。
与低或中心血管风险的个体相比，心血管风险较高的个体的8-iso-PGF值显著更高（<0.001）。在整个人群和肾功能正常的患者中，8-iso-PGF与Fr-S和ASCVD-S密切相关（均<0.001），但在估算肾小球滤过率（eGFR）<60 mL/min/1.73 m²的患者中则不然。在对总体人群和肾功能正常的患者的心血管风险方程中纳入的传统因素进行调整后，这些关联仍然显著。在总体人群中，最能区分高心血管风险患者的8-iso-PGF临界值，对于Fr-S为310 pg/mL，对于ASCVD-S为264 pg/mL，按eGFR分组的各亚组之间存在显著差异（均<0.001）。
这些发现突出了8-iso-PGF作为一种生物标志物在完善高血压患者心血管风险分层中的潜在效用，特别是对于肾功能保留的患者。未来的研究应探讨其在纵向队列中的预后价值，并评估其纳入临床风险模型以加强心血管疾病早期预防策略的情况。
